readthroughSign in
Nov 16, 2026Financing

Rezolute prices $100 million stock offering led by Frazier Life Sciences

The ultra-rare disease company plans to use proceeds to fund commercialization preparation for its hyperinsulinism antibody ersodetug.

Rezolute, Inc. announced on November 13, 2026 the pricing of an underwritten offering of 22,040,976 shares of common stock at $3.87 per share, along with pre-funded warrants to purchase up to 3,800,000 additional shares at $3.869 per warrant. The offering was priced for shares of common stock, and pre-funded warrants to purchase up to 3,800,000 shares of common stock, which represents the per share offering price for the common stock, less the $0.001 per share exercise price for each pre-funded warrant.1

Gross proceeds to Rezolute from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $100 million.1 According to the company's 8-K filing, estimated net proceeds of the offering to the company, after deducting underwriting discounts and commissions and offering expenses, are approximately $93.5 million.1

The closing of the offering is expected to occur on or about November 16, 2026, subject to satisfaction of customary closing conditions.1

The company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund ersodetug commercialization preparation and for working capital and general corporate purposes.1

The financing is being led by Frazier Life Sciences and includes participation from new and existing funds.1 Morgan Stanley, Guggenheim Securities, and Cantor are acting as joint book-running managers for the offering, with H.C. Wainwright & Co. and Jones serving as lead managers, and Maxim Group LLC and Lake Street Capital Markets, LLC as co-managers.1

The securities are being sold under a shelf registration statement on Form S-3. The shares and pre-funded warrants are being offered pursuant to a registration statement on Form S-3, File No. 333-299867, which was declared effective by the SEC on November 10, 2026.1

Regarding the company itself, Rezolute describes itself as a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism, with its antibody therapy, ersodetug, studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI.1

Separately, the filing notes that the company's executive officers and directors have agreed to a lock-up period restricting sales of common stock for 30 days following the final prospectus supplement, subject to certain exceptions and written consent from Morgan Stanley.1

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.